| TRV |
Report |
Core EPS |
BEAT |
pred ~$5.45 vs. cons $5.33 |
MEDIUM |
| TRV |
Report |
Consolidated Combined Ratio (lower=better) |
BEAT |
pred ~93.0% vs. cons ~94.3% |
MEDIUM |
| TRV |
Report |
Pre-tax Catastrophe Losses |
BEAT |
pred ~$1.10B vs. cons ~$1.30B |
LOW |
| TRV |
Guide |
FY2026 Expense Ratio guidance |
UNCHANGED |
guide ~28.5% vs. cons ~28.6% (FY2026) |
MEDIUM |
| TRV |
Guide |
Q3 2026 After-tax Fixed-Income NII guidance |
UNCHANGED |
guide ~$840M vs. cons ~$835M (Q3 2026) |
MEDIUM |
| TRV |
Guide |
Business Insurance renewal premium change / pricing-vs-loss-trend commentary |
LOWER |
guide ~4.0% vs. cons ~5.5% (Q2 2026) |
MEDIUM |
| TRV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| TRV |
Return |
5-day cumulative residual |
-3.5% (FADE) |
Even a headline EPS beat vs. an already-reduced ~$5.33 consensus is unlikely to hold up because (1) Q2 cat losses, while below the market's worst fears, still run well above last year's unusually clean $927M comp, compressing the YoY earnings growth story; (2) management's own admission that Business Insurance renewal pricing is now tracking below long-term loss trend implies analysts will trim out-period (2H26/FY26) underlying margin and EPS estimates even if Q2 itself clears the bar; (3) the Q1 equity-market pullback is flowing through alternatives NII with a one-quarter lag, a known headwind that could bite estimates for Q3 as well; and (4) TRV rallied ~16% into the print (much of it in the two weeks pre-earnings) while sell-side sentiment split sharply (Barclays UW, TD Cowen Sell, Evercore cut to In-Line right before the print), leaving the stock priced for perfection. That combination of stretched positioning plus implicit forward-estimate cuts points to a 'beat-but-fade' pattern over the week rather than durable follow-through. |
LOW |